AU2013308245B2 - Nanoparticle formulation - Google Patents

Nanoparticle formulation Download PDF

Info

Publication number
AU2013308245B2
AU2013308245B2 AU2013308245A AU2013308245A AU2013308245B2 AU 2013308245 B2 AU2013308245 B2 AU 2013308245B2 AU 2013308245 A AU2013308245 A AU 2013308245A AU 2013308245 A AU2013308245 A AU 2013308245A AU 2013308245 B2 AU2013308245 B2 AU 2013308245B2
Authority
AU
Australia
Prior art keywords
pct
continued
lita
nanoparticle
nanoparticle formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013308245A
Other languages
English (en)
Other versions
AU2013308245A1 (en
Inventor
Meliz Sahuri ARISOYLU
Jimmy Bell
Leigh BRODY
Gary Frost
Andrew Miller
Elizabeth Louise THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Kingdom Research and Innovation
Original Assignee
United Kingdom Research and Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Kingdom Research and Innovation filed Critical United Kingdom Research and Innovation
Publication of AU2013308245A1 publication Critical patent/AU2013308245A1/en
Application granted granted Critical
Publication of AU2013308245B2 publication Critical patent/AU2013308245B2/en
Assigned to UNITED KINGDOM RESEARCH AND INNOVATION reassignment UNITED KINGDOM RESEARCH AND INNOVATION Request for Assignment Assignors: IMPERIAL INNOVATIONS LTD, MEDICAL RESEARCH COUNCIL
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013308245A 2012-08-28 2013-08-28 Nanoparticle formulation Active AU2013308245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215289.8A GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation
GB1215289.8 2012-08-28
PCT/GB2013/052258 WO2014033453A1 (en) 2012-08-28 2013-08-28 Nanoparticle formulation

Publications (2)

Publication Number Publication Date
AU2013308245A1 AU2013308245A1 (en) 2015-04-09
AU2013308245B2 true AU2013308245B2 (en) 2018-03-29

Family

ID=47045497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013308245A Active AU2013308245B2 (en) 2012-08-28 2013-08-28 Nanoparticle formulation

Country Status (8)

Country Link
US (1) US10201499B2 (OSRAM)
EP (1) EP2890365B1 (OSRAM)
JP (1) JP6483017B2 (OSRAM)
CN (1) CN104837482B (OSRAM)
AU (1) AU2013308245B2 (OSRAM)
CA (1) CA2882705C (OSRAM)
GB (1) GB201215289D0 (OSRAM)
WO (1) WO2014033453A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
RU2017127597A (ru) * 2015-01-23 2019-02-25 Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен Применение короткоцепочечных жирных кислот для профилактики рака
CN106551902B (zh) * 2015-09-17 2020-07-03 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2018236190B2 (en) * 2017-03-13 2025-02-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
CN107049954A (zh) * 2017-06-12 2017-08-18 杭州普施康生物科技有限公司 一种药物组合及其制备方法和用途
CN110192651A (zh) * 2019-05-31 2019-09-03 浙江工业大学 一种利用大豆分离蛋白负载植物甾醇酯的纳米乳液的制备方法
CN111426659B (zh) * 2020-03-24 2023-06-06 深圳唯公生物科技有限公司 磁性荧光编码微球及其制备方法
US20250269003A1 (en) * 2022-04-22 2025-08-28 University Of Virginia Patent Foundation Nano-enhanced vaccine
KR20250107214A (ko) * 2022-11-10 2025-07-11 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 간질환 또는 간장애의 치료 또는 예방 방법
CN118105524B (zh) * 2024-03-14 2024-11-22 南京鼓楼医院 一种靶向肠上皮细胞的焦亡抑制剂药物递送系统及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305769A1 (en) * 2008-11-17 2011-12-15 Enzon Pharmaceuticals, Inc. Branched cationic lipids for nucleic acids delivery system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
IT1303787B1 (it) * 1998-11-25 2001-02-23 Maria Rosa Gasco "nanosfere lipidiche solide atte ad una rapida internalizzazione nellecellule"
EP1140022B8 (en) * 1998-12-18 2008-10-15 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6387952B1 (en) 2000-09-19 2002-05-14 Arco Chemical Technology L.P. Method of treating gastrointestinal disorders, particularly colitis
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
WO2006076734A2 (en) 2005-01-14 2006-07-20 Medical College Of Georgia Research Institute Prodrugs of short-chain fatty acids and treatment methods
US9315532B2 (en) 2005-05-24 2016-04-19 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
ITMI20051024A1 (it) 2005-06-01 2006-12-02 Maria Rosa Gasco Nuovo uso di nanoparticelle lipidiche solide
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2673622A1 (en) 2006-12-22 2008-07-03 Imuthes Limited Lipid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305769A1 (en) * 2008-11-17 2011-12-15 Enzon Pharmaceuticals, Inc. Branched cationic lipids for nucleic acids delivery system

Also Published As

Publication number Publication date
EP2890365A1 (en) 2015-07-08
GB201215289D0 (en) 2012-10-10
EP2890365B1 (en) 2019-11-20
CN104837482A (zh) 2015-08-12
CN104837482B (zh) 2018-09-18
CA2882705C (en) 2021-06-22
AU2013308245A1 (en) 2015-04-09
JP2015530382A (ja) 2015-10-15
US20150224054A1 (en) 2015-08-13
US10201499B2 (en) 2019-02-12
WO2014033453A1 (en) 2014-03-06
JP6483017B2 (ja) 2019-03-13
HK1211862A1 (en) 2016-06-03
CA2882705A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
AU2013308245B2 (en) Nanoparticle formulation
Wang et al. Kidney-targeted rhein-loaded liponanoparticles for diabetic nephropathy therapy via size control and enhancement of renal cellular uptake
Corbin et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
Li et al. Mr and fluorescent imaging of low-density lipoprotein receptors1
Wu et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging
Wu et al. Orally deliverable sequence-targeted fucoxanthin-loaded biomimetic extracellular vesicles for alleviation of nonalcoholic fatty liver disease
JP2003530362A (ja) 診断剤をターゲッティングするための脂質ベースの系
Kluza et al. Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity
Shi et al. An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety
Ding et al. “Sweet tooth”-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy
Yuba et al. Multifunctional traceable liposomes with temperature-triggered drug release and neovasculature-targeting properties for improved cancer chemotherapy
Wang et al. Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency
Gu et al. Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage
Zheng et al. Assessment of the preventive effect against diabetic cardiomyopathy of FGF1-loaded nanoliposomes combined with microbubble cavitation by ultrasound
JP2006335745A (ja) リポソームを含むｍｒｉ造影剤
Liu et al. Glucagon-modified liposomes delivering thyroid hormone for anti-obesity therapy
WO2012135550A1 (en) Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
Maiseyeu et al. Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging
CN113307824B (zh) 一种双亲性材料及其在制备脂质体中的应用
HK1211862B (en) Nanoparticle formulation
Cheng et al. A Novel Protein‐Polysaccharide Oral Nanoemulsion Targeting Activated Hepatic Stellate Cells to Enhance the Therapeutic Effect of Pirfenidone on Fibrosis After Transarterial Chemoembolization for Liver Cancer
WO2012153616A1 (ja) 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
Yu et al. Targeted delivery of empagliflozin via glycyrrhetinic-acid-modified lipid nanoparticles for metabolic dysfunction–associated steatotic liver disease therapy
Xiao et al. Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION

Free format text: FORMER OWNER(S): MEDICAL RESEARCH COUNCIL; IMPERIAL INNOVATIONS LTD